{"name": "Tekmira Pharmaceuticals",
 "permalink": "tekmira-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/tekmira-pharmaceuticals",
 "homepage_url": "http://www.tekmirapharm.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 76,
 "founded_year": 1992,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "604-419-3200",
 "description": "",
 "created_at": "Wed Sep 09 01:36:41 UTC 2009",
 "updated_at": "Wed Sep 09 01:36:41 UTC 2009",
 "overview": "\u003Cp\u003ETekmira Pharmaceutical Corporation, a biopharmaceutical company, develops and commercializes proprietary drugs and drug delivery systems for the treatment of cancer and other diseases. The company primarily focuses on the development of internal product candidates that include apolipoprotein B (ApoB) SNALP for the treatment of high cholesterol and polo-like kinase 1 (PLK1) SNALP for the treatment of cancer. It has a collaborative relationship with Alnylam Pharmaceuticals, Inc.; research relationships with Bristol-Myers Squibb Company, Roche, Johnson \u0026amp; Johnson Pharmaceutical Research \u0026amp; Development, and the US Army Medical Research Institute for Infectious Diseases; and licensing agreements with Hana Biosciences, Inc. for the development of Marqibo, Alocrest, and Brakiva, and with Aradigm Corporation. The company was founded in 1992 and is headquartered in Burnaby, Canada.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[147,
       65],
      "assets/images/resized/0005/9174/59174v1-max-150x150.jpg"],
     [[147,
       65],
      "assets/images/resized/0005/9174/59174v1-max-250x250.jpg"],
     [[147,
       65],
      "assets/images/resized/0005/9174/59174v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Mark",
      "last_name": "J. Murray",
      "permalink": "mark-j-murray",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Ian",
      "last_name": "C. Mortimer",
      "permalink": "ian-c-mortimer",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 32450000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "",
    "source_description": "Cap Funding Report",
    "acquired_year": 2008,
    "acquired_month": 3,
    "acquired_day": 28,
    "company":
     {"name": "Protiva Biotherapeutics",
      "permalink": "protiva-biotherapeutics",
      "image":
       {"available_sizes":
         [[[150,
            43],
           "assets/images/resized/0005/9173/59173v1-max-150x150.jpg"],
          [[206,
            60],
           "assets/images/resized/0005/9173/59173v1-max-250x250.jpg"],
          [[206,
            60],
           "assets/images/resized/0005/9173/59173v1-max-450x450.jpg"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "8900 Glenlyon Parkway",
    "address2": "Suite 200",
    "zip_code": "V5J 5J8",
    "city": "Burnaby, BC",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}